Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

NCT02528318 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate after 3 dosing groups

Conditions

Respiratory Distress Syndrome

Interventions

COMBINATION_PRODUCT: Lucinactant for inhalation
DEVICE: nCPAP alone

Sponsor

Windtree Therapeutics